[
  {
    "ts": "2025-12-16T06:05:01+00:00",
    "headline": "How Amgen’s New CD19-Targeted gMG Approval At Amgen (AMGN) Has Changed Its Investment Story",
    "summary": "Earlier this month, Amgen announced that the FDA approved UPLIZNA (inebilizumab-cdon) for adults with generalized myasthenia gravis who are anti-AChR and anti-MuSK antibody positive, making it the first and only CD19-targeted B-cell therapy for this condition with maintenance dosing just twice a year after loading. This latest indication, added to UPLIZNA’s existing approvals in neuromyelitis optica spectrum disorder and IgG4-related disease, further reinforces Amgen’s position in rare, B...",
    "url": "https://finance.yahoo.com/news/amgen-cd19-targeted-gmg-approval-060501756.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "57a0dc0a-d814-3e90-a268-9e90d8c3c51c",
      "content": {
        "id": "57a0dc0a-d814-3e90-a268-9e90d8c3c51c",
        "contentType": "STORY",
        "title": "How Amgen’s New CD19-Targeted gMG Approval At Amgen (AMGN) Has Changed Its Investment Story",
        "description": "",
        "summary": "Earlier this month, Amgen announced that the FDA approved UPLIZNA (inebilizumab-cdon) for adults with generalized myasthenia gravis who are anti-AChR and anti-MuSK antibody positive, making it the first and only CD19-targeted B-cell therapy for this condition with maintenance dosing just twice a year after loading. This latest indication, added to UPLIZNA’s existing approvals in neuromyelitis optica spectrum disorder and IgG4-related disease, further reinforces Amgen’s position in rare, B...",
        "pubDate": "2025-12-16T06:05:01Z",
        "displayTime": "2025-12-16T06:05:01Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/8ab44b8ef28c7f69299492d5b9c5a46c",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ACuIXYrNeojUXbAJFhnPIg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8ab44b8ef28c7f69299492d5b9c5a46c.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/B7CQJIEa.2c0sQ0XIU66pg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/8ab44b8ef28c7f69299492d5b9c5a46c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/amgen-cd19-targeted-gmg-approval-060501756.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/amgen-cd19-targeted-gmg-approval-060501756.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]